Molecular pathogenesis of autosomal dominant polycystic kidney disease
======================================================================

One's first glimpse of a specimen from a patient with advanced autosomal dominant polycystic kidney disease (ADPKD) creates a lasting impression. The massive enlargement of the kidney and the substitution of an irregular profusion of glistening cysts for its usual striated architecture are unmistakable hallmarks of a disease afflicting approximately 1 in 1,000 individuals ([@bib109]; [@bib14]; [@bib35]; [@bib51]; [@bib125]). The dramatic appearance underscores a single gene's power to alter grotesquely the morphology of an organ whose structure is normally sublimely intertwined with its function.

ADPKD cysts increase in size and number over the space of decades, displacing and destroying adjacent renal parenchyma, leading ultimately to end-stage renal disease in ∼50% of cases. Cardiovascular, musculoskeletal, and gastrointestinal abnormalities are also associated with ADPKD ([@bib29]). The *Pkd1* (polycystic kidney disease-1) and *Pkd2* (polycystic kidney disease-2) genes encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively. Approximately 85% of ADPKD cases are attributable to mutations in *Pkd1*, while mutations in *Pkd2* account for almost all of the remaining cases. During the past fifteen years an enormous amount of effort has been invested in exploring the functions of the PC1 and PC2 proteins. The return on this investment constitutes something of an embarrassment of riches, in that the polycystin proteins appear to participate in a nearly bewildering array of signaling pathways and regulatory processes, and to reside within a complex collection of subcellular structures. A major goal of current ADPKD research is to elucidate the connections between these cell biological properties of the polycystin proteins and the pathogenesis of the disease that develops when their expression is perturbed.

One of the most intriguing discoveries to emerge from this intense research is the realization that portions of the cellular populations of PC1 and PC2 localize to the primary cilium. ADPKD is the founding member of the "ciliopathies," a recently defined class of genetic disorders that result from mutations in genes encoding cilia-associated proteins. These disorders are often characterized by the presence of renal cysts as well as by additional pathologies including neural tube defects, retinal malformations, and polydactyly ([@bib5]). Although the cellular and molecular mechanisms responsible for the pathogenesis of ADPKD are still very much the subject of spirited and healthy debate, it has become clear in recent years that understanding ADPKD, and the function or dysfunction of PC1 and PC2, will require an appreciation of these proteins' roles in the primary cilium.

The polycystin proteins
=======================

Polycystin-1 structure and cleavage.
------------------------------------

PC1 is a 450-kD protein with a large extracellular N terminus, 11 membrane-spanning domains, and a shorter cytoplasmic C terminus ([@bib48]; [@bib79]). It is expressed in the epithelial cells of the developing and mature renal tubules, as well as in a variety of other somatic tissues including heart, liver, bone, and endocrine glands ([@bib122]; [@bib49]; [@bib72]; [@bib87]). Expression of PC1 is temporally regulated, with the highest levels found in fetal renal tissue and low but detectable levels present in adult tissue ([@bib19]). PC1 is found in the cilium, but also localizes to the lateral domain of the plasma membrane and adhesion complexes in polarized epithelial cells ([@bib49]; [@bib46]; [@bib128]; [@bib106]). In addition, PC1 and PC2 may be shed from the apical or ciliary membranes in urinary exosome-like vesicles that can interact with the primary cilium ([@bib42]).

The large extracellular PC1 N terminus contains 15 PKD repeat motifs, two complete leucine-rich repeat motifs flanked by cysteine-rich sequences, and a C-type lectin domain ([@bib48]; [@bib11]). Many of these domains are crucial for PC1's functions and play established roles in protein--protein or protein--matrix interactions ([@bib116]; [@bib50]; [@bib4]; [@bib106]). This evidence, combined with PC1's subcellular localization to the plasma membrane and junctional complexes, supports a role for PC1 in cell--cell and cell--matrix interactions. The extracellular domains of PC1 and PC2 may also participate in sensing fluid flow and pressure in the kidney, as reviewed by [@bib83]. The 200 amino acids of the PC1 C-terminal tail (CTT) contain a G protein--binding domain and a coiled-coil domain. The C-terminal tail of PC1 also contains a sequence that is rich in proline, glutamic acid, serine, and threonine (PEST) amino acids, which may facilitate its ubiquitin-mediated degradation ([@bib96]; [@bib67]).

Polycystin-1 undergoes cleavages in both its N- and C-terminal domains ([Fig. 1](#fig1){ref-type="fig"}). N-terminal cleavage occurs at the G protein--coupled receptor proteolytic site (GPS), just before the first transmembrane domain ([@bib94]). This is a cis-autoproteolytic cleavage that occurs early in the secretory pathway, and the cleaved PC1 N terminus remains noncovalently attached to the membrane-bound C-terminal fragment ([@bib123]). Not all of the PC1 molecules in a cell are cleaved, generating a heterogeneous population of full-length and GPS-cleaved PC1 proteins ([@bib123]; [@bib129]). To be fully functional PC1 must be able to undergo N-terminal cleavage. Expression of a mutant form of PC1 that cannot undergo GPS cleavage does not rescue *PC1*-null cultured cells or transgenic mice. In addition, this missense mutation causes ADPKD in humans ([@bib94]; [@bib126]; [@bib129]).

![**N- and C-terminal cleavage of the PC1 protein.** The N terminus of PC1 is cleaved at the G protein--coupled receptor proteolytic site (GPS), but the extracellular domain remains noncovalently attached to the membrane-bound portion of the protein. Either of two different cleavages can release C-terminal tail fragments that translocate to the nucleus with components of the Wnt pathway, STAT6/p100, and perhaps with other regulators of transcription. At least one of the C-terminal tail cleavages is stimulated by the presence of PC2, and this stimulation requires that PC2 be capable of functioning as an ion channel.](JCB_201006173_RGB_Fig1){#fig1}

Two other cleavages liberate the cytoplasmic CTT of PC1 ([Fig. 1](#fig1){ref-type="fig"}). [@bib20] observed a cleavage that releases an ∼35-kD soluble portion of the tail that accumulates in the nucleus in response to decreased fluid flow in the mouse kidney. [@bib67] observed a second, more distal cleavage that releases a 15-kD fragment of the PC1 cytoplasmic tail that interacts with the transcriptional activator STAT6 and the coactivator p100. Flow cessation increased this PC1 cleavage and nuclear translocation of both the PC1 tail and STAT6 ([@bib67]). Interestingly, an increased level of cleaved CTT is observed in cells lining ADPKD cysts ([@bib67]). At least one of these C-terminal cleavages is stimulated by the presence of PC2, and this stimulation requires that PC2 be competent to function as an ion channel ([@bib7]). Although the sizes of these fragments have been identified and their production is apparently regulated, the amino acid sequences of both cleavage sites have yet to be determined.

Polycystin-2 structure and channel function.
--------------------------------------------

Polycystin-2 (PC2 or TRP2) is a 968-amino acid protein that spans the membrane six times, with intracellular N and C termini ([@bib74]). PC2 functions as a Ca^2+^-permeable nonselective cation channel and is homologous to the transient receptor potential family of cation channels ([@bib114]; [@bib33]). Although a portion of PC2 colocalizes with PC1 to the cilium, the majority of the cellular pool of PC2 appears to reside in intracellular compartments, where it may modulate the release of calcium from intracellular stores. The channel activity of the ciliary pool of the PC1--PC2 complex appears to respond to ciliary bending, and may also mediate the cilium's role in transducing other mechanical or chemical stimuli ([@bib78]).

Several domains present in PC2's N and C termini are responsible for PC2's protein--protein interactions and Ca^2+^ sensitivity. At least two domains, one in each cytoplasmic tail, contribute to PC2 oligomerization. Immediately distal to PC2's last transmembrane domain is a functionally complex region of the C terminus that includes coiled-coil, EF-hand, and ER retention domains. A calcium-binding EF hand domain begins upstream of and extends into the PC1-interacting coiled-coil region ([@bib74]; [@bib93]; [@bib17]). The helix-loop-helix structure of the EF-hand binds Ca^2+^, permitting the protein to sense or to buffer changes in Ca^2+^ ([@bib32]). The PC2 EF-hand has a single Ca^2+^-binding site with micromolar affinity ([@bib17]). Slightly overlapping with both the coiled-coil and the EF-hand is a sequence that is required for maintaining PC2's ER and Golgi localization ([@bib12]). A naturally occurring truncation mutation that removes this C-terminal domain, and thus presumably abrogates all of its interactions and regulatory potential, is sufficient to cause ADPKD ([@bib74]).

PC2 is a calcium-activated channel that releases calcium from intracellular stores in response to local increases in calcium concentrations ([@bib117]; [@bib58]). The calcium-conducting pore of PC2 is likely formed by the loop between the fifth and sixth transmembrane domains, with some involvement of the third transmembrane domain ([@bib22]; [@bib58]). A missense mutation that perturbs this putative conducting pore (D511V) is causative of ADPKD ([@bib58]). Fine-tuning PC2's Ca^2+^ response and channel properties involves post-translational modifications, such as phosphorylation at S812 by casein kinase II, and binding of protein partners ([@bib13]; [@bib99]). For a more thorough discussion of PC2 channel activity see the review by [@bib15].

PC2 also indirectly regulates cytoplasmic calcium levels through interactions with two major intracellular Ca^2+^ channels: the ryanodine receptor and the inositol 1,4,5-trisphosphate receptor (IP3R). The ryanodine receptor mediates calcium-induced calcium release, and PC2 inhibits its function by binding the channel in its open state and decreasing its conductance ([@bib2]). PC2 also modifies IP3-induced Ca^2+^ flux through direct binding between the PC2 C terminus and the IP3R ([@bib65]).

Polycystin-2 localization and trafficking.
------------------------------------------

PC2 localizes to several subcellular compartments ([@bib56]; [@bib115]). The largest pool of PC2 is found in the ER and early Golgi ([@bib12]; [@bib58]). Functional PC2 is also found at the plasma membrane, where it may exist in complexes with PC1 ([@bib38]; [@bib86]; [@bib130]). Pools of PC2 also reside in more restricted subcellular domains, such as the primary cilium and mitotic spindles ([@bib128]; [@bib78]; [@bib99]; [@bib126]).

A set of very specific signal sequences and trafficking proteins helps establish and maintain PC2 at these subcellular locations. Retention of PC2 in the early secretory pathway involves proteins that bind to the PC2 C terminus. A stretch of acidic amino acids in the protein's C terminus functions as an ER retention signal by binding phosphofurin acidic cluster--sorting protein (PACS)-1 and PACS-2 ([@bib12]; [@bib57]). PACS-2 seems to be capable of ensuring that PC2 remains localized to the ER, whereas PACS-1 brings PC2 from endosomal compartments back to the TGN. The binding between PC2 and the PACS proteins requires PC2 phosphorylation by casein kinase II (CK2) ([@bib57]) Facilitating PC2--PACS binding is one of the several roles for CK2 in altering PC2 localization. Experiments in *Caenorhabditis elegans* show that a mutation that prevents phosphorylation at a CK2 site in the PC2 orthologue protein promotes its localization to cilia, and this localization is prevented by a phospho-mimetic mutation at the same site. Consistent with this model, the calcineurin phosphatase TAX-6 is required for the PC2 orthologue's ciliary localization in *C. elegans* ([@bib45]). One of the other CK2 recognition sites in PC2 appears to exert no effect on the protein's localization, but its phosphorylation is required for PC2 channel function ([@bib13]). Thus, the multiple effects of CK2-mediated phosphorylation demonstrate a potential connection between mechanisms that regulate PC2's localization and function.

Regulation of PC2 movement from the ER to the Golgi is also controlled by another protein that binds to the PC2 C-terminal tail. PIGEA-14 (polycystin-2 interactor, Golgi- and endoplasmic reticulum--associated protein), also called Chibby, is a 14-kD protein that binds to the Golgi matrix protein GM130. Co-expressing PIGEA-14 with PC2 in culture cells causes a redistribution of PC2 from the ER to the TGN ([@bib41]).

Mechanisms for targeting PC2 to the primary cilium and mitotic spindles appear to rely on novel motifs and protein trafficking machinery. A 15-amino acid R~6~VxP motif at the very beginning of PC2's N terminus is sufficient to ensure PC2's localization to the primary cilium ([@bib31]). Targeting PC2 to the mitotic spindle of dividing cells requires mammalian diaphanous 1 (mDia1), which belongs to a protein subfamily involved in cytoskeletal rearrangements and cytokinesis. Interestingly, mDia1 binding to PC2 also modulates PC2's channel activity and is subject to regulation by growth factors, suggesting an interesting but as-of-yet unexplored connection between PC2 channel function and mitosis ([@bib99]).

Interaction between PC1 and PC2.
--------------------------------

The subcellular localizations of PC1 and PC2 overlap and may, in some locations, be functionally codependent. There is strong colocalization of both proteins to the primary cilium, and they are also found together in the ER ([@bib128]). Several investigations suggest that PC1 and PC2 may reciprocally affect each other's surface membrane or ciliary localizations, although the precise nature of this interdependence has varied somewhat among experimental systems ([@bib38]; [@bib37]; [@bib4]). Studies performed on cells derived from ADPKD cysts indicate that impairing the function of one protein negatively affects the localization of the other: cells expressing an ADPKD-associated PC1 mutation that prevents GPS cleavage have decreased amounts of both PC1 and PC2 in their primary cilia ([@bib126]). An interaction between PC1 and PC2 has also been suggested to be important in creating a functional ion channel, whether through activation of the PC2 protein's intrinsic channel properties or through emergent channel properties attributable to formation of the complex ([@bib38]; [@bib25]). Physically, the interaction between the two proteins is thought to occur primarily through their C-terminal cytoplasmic tails ([@bib93]; [@bib113]; [@bib16]). This interaction also appears to influence the proteins' functional properties, as interaction of PC2 with PC1 decreases the ability of PC1 to activate G proteins ([@bib24]).

Signaling pathways modified by PC1 and PC2
==========================================

The polycystin proteins modulate diverse signaling pathways, and there is a long list of proteins known to interact with PC1 or PC2 ([@bib104]). To summarize broadly, however, the evidence highlights three general themes in the relationship between the PC1 and PC2 proteins and cellular signaling pathways: negative growth regulation, G protein activation, and Wnt pathway modulation ([Fig. 2](#fig2){ref-type="fig"}). Although the mechanism for the PC1- or PC2-dependent effect in each case varies, a frequent theme is that the PC1 CTT binds to and negatively regulates the activity of crucial signaling molecules. In some cases this negative regulation happens at the cell membrane, and may be attributable at least in part to the sequestration at the cell surface of signaling protein partners that would otherwise enter the nucleus to modulate signaling. In other cases the cleaved PC1 CTT itself travels to the nucleus, where it appears to influence transcriptional activities. In each case, misregulating PC1 expression or cleavage appears to result in aberrant signaling, which may in turn lead to the abnormal cellular growth behaviors that are likely to contribute to ADPKD pathogenesis.

![**PC1 and PC2 affect multiple signaling pathways.** Summary of the effects that PC1 and PC2 exert on signaling pathways. Multiple direct and indirect interactions allow the polycystin proteins to inhibit or stimulate pathways involved in cellular growth and differentiation.](JCB_201006173_RGB_Fig2){#fig2}

Growth regulation.
------------------

Elevated cellular growth rates are a hallmark of ADPKD, so it is no surprise that the polycystin proteins negatively regulate cellular growth and division through several pathways, which are diagrammed in [Fig. 2](#fig2){ref-type="fig"} (see also the recent review by [@bib132]). One significant effect of PC1 involves inhibition of the mTOR (mammalian target of rapamycin) cascade ([@bib102]; [@bib27]; [@bib26]). This effect is mediated by the TSC1 and TSC2 (tuberous sclerosis 1 and 2) complex, which acts as a negative regulator of the mTOR complex ([@bib47]). The TSC2--TSC1 complex acts as a GTPase-activating protein for the small GTP-binding protein Rheb, which must be in its GTP-bound state in order for the mTOR kinase to function. PC1 decreases mTOR activity by stabilizing the functional TSC1--TSC2 complex via two distinct mechanisms. PC1 decreases ERK-dependent phosphorylation of TSC2 at S664 ([@bib27]), which allows TSC2 to remain bound to TSC1 ([@bib69]). The TSC1/2 complex is also stabilized by the binding of PC1 to TSC2 at the plasma membrane, protecting TSC2 from phosphorylation by Akt at S939 ([@bib26]), thus allowing the protein complex to continue repressing mTOR signaling ([@bib53]). The influence of the PC1--TSC2 interaction may not be unidirectional; expression of TSC2 may help PC1 to reach the plasma membrane ([@bib55]).

Cell cycle progression is governed by cyclin-dependent kinases (Cdks), and p21 slows or halts cell cycle progression by inhibiting Cdk2. The polycystin proteins act in concert to positively regulate p21 expression and activity. PC1 can increase p21 levels by binding members of the Janus kinase (JAK) and signal transducers and activators of transcription (STAT) pathway. PC1 activates STAT1 and STAT3, thus elevating p21 levels and decreasing cell growth. This activation requires a PC2-dependent interaction with JAK2, and also requires that PC1 have an intact C terminus ([@bib8]). PC2-dependent mechanisms also prevent the nuclear localization of Id2 and E47, two p21-repressing helix-loop-helix proteins ([@bib64]). PC2 also reduces cell growth through direct physical interaction with eukaryotic translation elongation initiation factor 2a (eIF2a). This translation factor is activated through phosphorylation by pancreatic ER-resident eIF2a kinase (PERK). PC2 binds both PERK and eIF2a, enhancing eIF2a's phosphorylation and decreasing cell proliferation ([@bib66]).

G protein activation.
---------------------

The PC1 CTT contains a highly conserved trimeric G protein activation domain ([@bib81]). G protein α-subunits activated by PC1 go on to positively regulate the activity of the c-Jun N-terminal kinase (JNK) and the AP-1 transcription factor ([@bib82]). AP-1 controls differentiation, apoptosis, and proliferation through a complex network of signaling and binding proteins ([@bib101]). In addition, PC1 activates JNK through PKC-α ([@bib3]). Abnormal levels of AP-1 activity in tissue from ADPKD cysts support the conclusion that polycystin proteins play an important role in regulating AP-1 ([@bib62]).

The interaction between PC1 and G proteins also activates the nuclear factor of activated T cells (NFAT). The NFAT pathway regulates genes involved in apoptosis, growth, cellular differentiation, and cell adaptation ([@bib44]). Exogenous expression of PC1 causes NFAT nuclear accumulation, and this effect is enhanced by coexpressing Gα~q~, a known PC1-binding G protein subunit ([@bib91]). NFAT can act in concert with AP-1 to turn on genes with composite transcription factor binding sites ([@bib70]). Both NFAT and AP-1 are activated by PC1-activated G proteins and it is possible that they may have combinatorial effects; however, there are currently no data supporting cooperativity between activated NFAT and AP-1 in PC1 signaling.

NFAT is connected in interesting ways to calcium signaling and PC2 localization. NFAT is activated by calcineurin which, in turn, is activated by sustained elevation of cytosolic Ca^2+^ levels. Activated calcineurin dephosphorylates NFAT, leading to its nuclear accumulation. NFAT rephosphorylation by glycogen synthase kinase 3β (GSK-3β) causes NFAT to move back into the cytoplasm ([@bib44]). Expressing PC1 presumably activates calcineurin through G proteins, leading to NFAT dephosphorylation and nuclear accumulation. In *C. elegans*, calcineurin-mediated dephosphorylation of PC2 permits this protein's ciliary localization ([@bib45]). [@bib91] found that inhibiting the PC2-modulated inositol triphosphate or ryanodine receptor channels impaired PC1's ability to regulate NFAT. It is thus tempting to suggest a connection between PC2's effect on cytoplasmic calcium and the NFAT signaling pathway, the activation of calcineurin, and the localization of PC2. Further research will be needed to unravel this network of interaction.

Canonical and noncanonical Wnt signaling.
-----------------------------------------

The Wnt pathways affect growth, differentiation, and establishment of planar cell polarity. PC1 seems to have a profound influence on both the canonical (β-catenin dependent) and noncanonical (β-catenin independent) components that make up the Wnt signaling network. ADPKD cysts and PC1-null cells manifest up-regulation of Wnt signaling activity markers, suggesting that PC1 exerts a negative effect on this system ([@bib59]; [@bib39]; [@bib105]). In the canonical pathway, the presence of the Wnt ligand induces β-catenin stabilization and nuclear translocation, leading to T cell factor (TCF)--dependent transcriptional activity. Cleaved PC1 CTT inhibits this pathway by directly or indirectly binding to β-catenin, moving with it to the nucleus, and reducing its ability to promote TCF-dependent transcription ([@bib59]). PC2 may also regulate the expression of some components of the Wnt pathway. Knocking out PC2 in cultured mouse cells resulted in increased levels of β-catenin protein ([@bib54]). Both PC1 and PC2 can therefore influence canonical Wnt signaling; however, it is currently unclear whether the effects of PC2 knockout on β-catenin levels are a direct result of the lack of PC2, or an indirect effect of PC1 misregulation caused by PC2 absence.

PC1 may also regulate noncanonical Wnt signaling, which is in turn related to the maintenance of planar cell polarity. The cells lining renal tubules generally divide parallel to the tubule's axis, lengthening the tubule rather than expanding its diameter. Tubule-lining cells in models of polycystic kidney disease, however, show a tendency to divide at an angle to the tubule's axis, which could lead to expansion of the tubule diameter. This deviation can occur before cysts appear, suggesting that a loss of this planar cell polarity may be a precursor to cyst formation ([@bib28]; [@bib84]).

Mechanisms of cyst formation
============================

Although ADPKD is genetically dominant at the organismal level, it is recessive at the cellular level. The kidneys of an ADPKD patient who inherits one mutated copy of PC1 or PC2 from a parent will develop and function normally into adulthood. Over time, however, cysts will form in this patient's kidneys and several studies suggest that the cells that line these cysts will have lost both functional copies of a polycystin gene ([@bib92]; [@bib9]). This indicates that an additional "second hit" somatic mutation may cause cysts to form. According to this model, each cyst arises as a consequence of a distinct somatic mutation event, explaining the disease's slow progression over the course of decades. Subtler factors may also impact upon disease progression, including the level of PKD1 protein expression, the penetrance of pathogenic alleles, and the stage of kidney development affected by *PKD1* mutation ([@bib68]; [@bib97]; [@bib90]; [@bib60]; [@bib98]). Temporally controlled inactivation of PC1 or PC2 expression in the kidneys of mice has revealed that loss of these proteins in the developing kidney causes far more severe cystic disease than does loss of PC1 or PC2 in the mature kidney ([@bib61]; [@bib88]; [@bib107]). These data suggest that loss of polycystin function during the period of rapid cell growth and division that characterizes post-natal renal development creates a predisposition toward cystogenesis, whereas polycystin function is far less critical after this period of cell proliferation ends.

The slow accumulation of cysts throughout adult life may be due to slow accumulation of inactivating "second hit" mutations as a result of a constant somatic mutation rate. It is also possible that, as individuals age, their kidneys are more likely to suffer transient obstructive or ischemic injuries to the tubule epithelial cells. These injuries would then stimulate repair, which involves cellular growth and division. Given the importance of PC1 and PC2 for cellular growth and differentiation, the decreased levels of functional polycystin proteins present in the cells of individuals heterozygous for ADPKD mutation could perturb the repair process and thus lead to cyst formation. Support for this pathway to cystic disease comes from studies in mice subjected to a renal injury, which initiates an up-regulation of cell growth and division. Kidneys heterozygous for *PKD1* or *PKD2* mutations cannot repair themselves as effectively as kidneys from wild-type mice, and accumulate more tubule dilation and microcysts than wild-type kidneys ([@bib6]; [@bib89]). Knocking out PKD1 expression in adult mouse kidneys causes a similar sensitivity to injury ([@bib108]). These results suggest that injury may be able to initiate cyst formation in heterozygotes without a requirement for a somatic "second hit" mutagenesis event. In addition, injury accelerates cyst formation in mouse models with slowly progressive cystic disease secondary to conditional inactivation of *PKD1* or *PKD2* in adulthood. It is possible, therefore, that the initiation of cyst formation could hinge upon the occurrence of either a somatic mutagenesis or an injury event, either of which could be seen to constitute a "second hit" that conspires with heterozygosity at one of the PKD loci to cause disease.

Cyst expansion.
---------------

The macroscopic consequence of ADPKD progression is the formation of fluid-filled cysts, which constitute a stark contrast to the normally compact arrangement of tubules in a healthy kidney ([Fig. 3](#fig3){ref-type="fig"}). At the cellular level, this transformation is predicated upon two alterations: cells must organize themselves to create spherical rather than tubular structures, and the lumens of these structures must fill with fluid in order to expand the consequent cysts. Cysts increase their surface areas primarily by increasing the number of cells that surround the cyst lumens rather than by simply stretching this epithelial layer ([@bib34]; [@bib36]). Thus, one model for the change from tubular to spherical morphology posits that perturbations in planar cell polarity cause tubular epithelial cells to no longer divide along an axis parallel to the tubule lumen, causing tubule expansion rather than elongation. Such a shift was seen in the axes of division in tubules of a rat cystic kidney model ([@bib28]). A close analysis of precystic tubules in mouse models manifesting kidney-specific inactivation of *PKD1* or *PKD2*, however, showed that cells lining cystic tubules lose orientated division after tubules began to dilate ([@bib80]). More dramatically, [@bib80] also found that misoriented cellular division is not sufficient for cyst development. Mice with a mutation in the ciliary protein fibrocystin have altered mitotic orientation but do not form kidney cysts because the cells that divide out of the epithelial plane migrate back into the tubule lining. Thus, it is likely that defects in planar cell polarity play a role in cyst formation, but losing this polarity may not be the event that initially causes cyst formation.

![**Cyst formation at the level of the cell, nephron, and kidney.** Defects in the genes encoding PC1 or PC2 lead to aberrant gene transcription, cell proliferation, and ion secretion, which in turn result in the formation of fluid-filled cysts. As cysts balloon out from individual nephrons, their collective effect leads to the displacement of the normal renal parenchyma and the formation of a cyst-filled kidney with reduced functional capacity.](JCB_201006173_RGB_Fig3){#fig3}

The other critical aspect of cyst formation, which involves the expansion of cyst fluid volume, can be understood as the conversion of the cyst-lining cells from an ion-absorptive to an ion-secretory epithelium. Ion secretion into the lumen then drives paracellular or transcellular osmotic water movement into the cyst, as illustrated in [Fig. 3](#fig3){ref-type="fig"}. A prime component of this secretion is Cl^−^ transport stimulated by cAMP ([@bib34]). The fluid movement driving cyst formation is stimulated by cAMP and involves the apical cystic fibrosis transmembrane regulator (CFTR) and the basolateral Na^+^-K^+^-2Cl^−^ cotransporter NKCC1 ([@bib23]; [@bib71]; [@bib75]). PC1 may affect the expression, localization, or activity of Cl^−^ channels. Expressing full-length PC1 with the CFTR channel in cultured MDCK cells decreases CFTR surface localization and cAMP-stimulated channel activity, suggesting that PC1 misregulation in ADPKD may lead to an increase in CFTR activity ([@bib52]). Expressing just the C-terminal tail of PC1 seems to enhance Cl^−^ transport, prolonging ATP-stimulated Cl^−^ conductance in transfected collecting duct cells and up-regulating Cl^−^ transport in *Xenopus* oocytes ([@bib124]; [@bib21]). The polycystin proteins may also regulate cAMP levels because cystic disease is associated with misregulation of phosphodiesterases that break down cAMP ([@bib121]).

Emerging treatment strategies
=============================

Clearly, no single unifying mechanism relates the normal functions of the polycystin proteins to the pathology that develops in their absence. It is, however, probably safe to assert that the progression of cystic disease is predicated upon perturbations in two fundamental processes. The epithelial cells that line cysts appear to proliferate excessively and these cells secrete rather than absorb fluid and electrolytes. Thus, many current efforts aimed at developing small molecule therapies for ADPKD target one or the other of these derangements ([@bib18]; [@bib40]; [@bib85]).

Because fluid secretion into cyst lumens is mediated, at least in part, by apical CFTR chloride channels and is stimulated by cAMP, both of these factors may constitute promising molecular targets. The CFTR inhibitor compound CFTRinh172 appears to substantially slow cyst expansion ([@bib127]). Inhibition of a basolateral potassium channel whose activity is required to maintain the electrochemical potential that drives chloride and fluid secretion is also being explored as an approach to blocking cyst fluid accumulation ([@bib1]).

Antidiuretic hormone (ADH), acting through the V2 vasopressin receptor, is a major stimulant of cAMP production in the collecting tubule of the kidney. Tolvaptan, a V2 receptor antagonist, dramatically reduces cyst progression in mouse models of ADPKD ([@bib30]; [@bib111]; [@bib120]; [@bib110]). Ocreotide, a somatostatin analogue, also inhibits cAMP accumulation in several cell types and has produced intriguing results in animal models ([@bib73]; [@bib43]).

The observation that inappropriately high mTOR activity may contribute to the excessive growth and proliferation that characterize cystic tissue has prompted investigations into the utility of mTOR inhibitors in the setting of ADPKD ([@bib103]; [@bib118]; [@bib27]; [@bib131]; [@bib26]; [@bib112]). Animal studies have suggested dramatic beneficial effects, although recent clinical trial data suggest that these results are not borne out in ADPKD patients, and the side effects of chronic mTOR inhibition may be substantial enough to further limit its potential utility ([@bib100]; [@bib112]; [@bib119]). Other efforts have directly targeted the regulation of mitosis. Roscovitine, an anti-proliferative drug that blocks Cdks, dramatically slows cyst formation in at least some animal models of PKD ([@bib10]).

Additional emerging potential therapies are directed at other interesting targets. These include triptolide, a compound derived from a traditional Chinese herbal therapy ([@bib63]); pioglitazone, a PPAR-γ agonist ([@bib76]; [@bib95]); and Genz-123346, which blocks glycosyl ceramide synthesis ([@bib77]). The connection between these compounds' molecular targets and the pathological processes involved in ADPKD remain to be determined. Further exploring these molecules, however, may reveal promising new pharmacological approaches to treating this disease and may also shed light on as-yet-undiscovered connections between the polycystin proteins and a variety of cellular signaling and metabolic pathways.

Conclusion
==========

ADPKD is a disease that merits the attention of cell biologists. The responsible genes have been identified, but much remains to be learned about the functions of the proteins they encode. Although it is clear that both polycystin-1 and -2 influence and are influenced by a wide array of signaling pathways, the connection between these pathways and the pathogenesis of the disease has yet to be definitively established. Furthermore, critical to any understanding of polycystic kidney disease will be a deeper insight into the nature of a mysterious and fascinating organelle, the primary cilium. Insights into how the polycystins traffic into the cilium, and what they do once they arrive there, will shed light not only on ADPKD, but also on novel and fundamental processes in cell biology.
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